Sunitinib Malate

For research use only.

Licensed by Pfizer Catalog No.S1042

65 publications

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit. Sunitinib Malate effectively inhibits autophosphorylation of Ire1α. Sunitinib Malate increases both death receptor and mitochondrial-dependent apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 57 In stock
USD 97 In stock
USD 147 In stock
USD 257 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Sunitinib Malate has been cited by 65 publications

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit. Sunitinib Malate effectively inhibits autophosphorylation of Ire1α. Sunitinib Malate increases both death receptor and mitochondrial-dependent apoptosis.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 M1fKVWtqdmG|ZTDBd5NigQ>? NHjQdoNKdmirYnn0bY9vKG:oIGDES2YucW6mdXPl[EBDemSXIHnuZ49zeG:{YYTpc44hf2m2aDDJR|UxKG:oIECuNFA4KM7:TR?= MlXaNVI3PDZyMUm=
3T3 NUfid5A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJcohq[mm2aX;uJI9nKFCuYYTlcIV1NWSncnn2[YQh\3Kxd4ToJIZi[3SxcjDpcoR2[2WmIEPUN{Bk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIECuNFEh|ryP NYP6bHNJOTJ4NE[wNVk>
3T3 NXT4cJhlTnWwY4Tpc44hSXO|YYm= MkDETY5pcWKrdHnvckBw\iCYYYPjeYxieiCnbnTveIhmdGmjbDDndo94fGhiZnHjeI9zKHKnY3XweI9zKHerdHigTWM2OCCxZjCwMlA2KM7:TR?= MX6xNlY1PjBzOR?=
3T3 MUHLbY5ie2ViQYPzZZk> MlLQNlAhdWmw NYf4dJRbTE2VTx?= MWPD[YxtfWyjcjDpcohq[mm2aX;uJI9nKF[HR1[gbY5lfWOnZDDoeY1idiCNRGKgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjB{MjFOwG0> NGHqfo8yPjF4MkCwPC=>
NIH3T3 MUTLbY5ie2ViQYPzZZk> M{LW[FIxKG2rbh?= M{\nU2ROW09? NEPDPWNqdmirYnn0JIh2dWGwIFvEVkBscW6jc3Wg[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iByLkCxPEDPxE1? MmDCNVYyPjJyMEi=
A549 NVnqemFzTnWwY4Tpc44hSXO|YYm= MUnEUXNQ NH;YfIlKdmirYnn0bY9vKG:oIHOtUYV1KGSncHXu[IVvfCCKR1[tbY5lfWOnZDDoeY1idiCDNUS5JINmdGxibXnndoF1cW:wIIfpeIghUUN3MDDv[kAzKM7:TR?= NGP2dJEyQDR|NEG0OS=>
DU145 MofUSpVv[3Srb36gRZN{[Xl? MkfTSG1UVw>? MnHtTY5pcWKrdHnvckBw\iClLV3leEBl\XCnbnTlcpQhUEeILXnu[JVk\WRiaIXtZY4hTFVzNEWgZ4VtdCC|Y3H0eIVzcW6pIIfpeIghUUN3MDDv[kAyOCEQvF2= MY[xPFQ{PDF2NR?=
KB3-1 NXfSXpNUS3m2b4TvfIlkKEG|c3H5 Ml:0O|IhcA>? M4HXXWROW09? M4PaVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHAu\3BvbnXnZZRqfmViS1KtN{0yKGOnbHzzJJdqfGhiSVO1NEBw\iB{LkOg{txO NYDDS3EyOTl|OUezNlI>
KBV1 NGXrPVREgXSxdH;4bYMhSXO|YYm= MUW3NkBp MU\EUXNQ MlfiR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVE1odHmlb4Dyc5RmcW5vZYjwdoV{e2mwZzDLRnYyKGOnbHzzJJdqfGhiSVO1NEBw\iB2LkGg{txO MWmxPVM6PzN{Mh?=
A375 NFrLepdEgXSxdH;4bYMhSXO|YYm= NEDyenE4OiCq MV7EUXNQ MnzmTWM2OD13LkSg{txO MY[xPVY2PDRyOB?=
RS4-11 NWr4UXNqTnWwY4Tpc44hSXO|YYm= NVv0VndqOiCq NYXQ[YR7UW6qaXLpeIlwdiCxZjDGUHQ{KGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB7OTFOwG0> NW\zWVl[OTl4NUS0NFg>
RS4-11 NGr5SXJHfW6ldHnvckBCe3OjeR?= NW\lTlMyOiCq MVrJcohq[mm2aX;uJI9nKE[OVEOgTXRFKG23dHHueEBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlA{PCEQvF2= NFu5PZAyQTZ3NESwPC=>
Sf9 NGiwclBMcW6jc3WgRZN{[Xl? M2LZVlMxKG2rbh?= MWrJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiVlXHSnIh\XiycnXzd4VlKHerdHigTWM2OCCxZjCwMlE5PSEQvF2= NEnPTnUyQTh3NEC1NS=>
Ba/F3 NGTTSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3GO|IhcA>? MoDLTWM2OD1zLkKg{txO NYT2S|ZWOjBzMUewNFQ>
BaPTC2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zLd|czKGh? Mo\1TWM2OD1yLkKyJO69VQ>? M1zRXFIxOTF5MEC0
Sf9 NEjPNndHfW6ldHnvckBCe3OjeR?= NWXNWHpuOSCq M1P5e2ROW09? MlrDTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKaYOteIFo\2WmIGLFWEBmgHC{ZYPz[YQhf2m2aDDJR|UxKG:oIEGuN{DPxE1? NVrjSm5qOjBzMUewNFQ>
H4 NFniPINEgXSxdH;4bYMhSXO|YYm= NUPSWW14OTBizszN NXnqZYRUXG:6aXPpeJkhcW5iaIXtZY4hUDRiY3XscJM> MlfpNlA{PTB6ME[=
SF-539 NFu0NpZMcW6jc3WgRZN{[Xl? NHPBTHc{OzNizszN NUjTTXJTPjBibXnu MW\EUXNQ M1i5T2lvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNVIvOiEQvF2= MlXyNlA1ODN5MEC=
U251 NIfPNIdMcW6jc3WgRZN{[Xl? MlXRN|M{KM7:TR?= NFrDPWQ3OCCvaX6= MWjEUXNQ MV\Jcohq[mm2aX;uJI9nKF[HR1\SNkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDF6Lkmg{txO NEfUNm0zODRyM{ewNC=>
A431 MknVT4lv[XOnIFHzd4F6 NX:5ZVZrUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGg[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iBzMj6yJO69VQ>? NVvFV3dWOjB3NUiwO|I>
A431 NGHONXZMcW6jc3WgRZN{[Xl? M1rj[WlvcGmkaYTpc44hd2ZiVlXHSnIzKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNVgvQSEQvF2= Mo[wNlA2PThyN{K=
HepG2 M{i1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;mb45WPzJiaB?= NXfZWol{UUN3ME2zMlgyKM7:TR?= NYLtSos1OjB3N{C1NlY>
Kasumi-1 NXTqdmVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrpVYJXPzJiaB?= MUHJR|UxRTBwMEG2JO69VQ>? MkfXNlA2PzB3Mk[=
RS4-11 M1i2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK1cFl7PzJiaB?= NFjwPWZKSzVyPUGg{txO M2TkNVIxPTdyNUK2
THP1 NYPpN3RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TZd|czKGh? NF;rUFVKSzVyPUCuOUDPxE1? MUGyNFU4ODV{Nh?=
Kasumi-1 NXz3R483TnWwY4Tpc44hSXO|YYm= MoD0TY5pcWKrdHnvckBw\iClLVvpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAyPSEQvF2= NIT4e2EzODh|M{CzPS=>
A549 M2HUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;SNVYhcA>? NYjUOZVYSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsdy=> NGTBNJIzOTR3MES2Ny=>
HL60 NILxcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLRclAyPiCq MVPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy| MkTVNlE1PTB2NkO=
HUVEC NH\3WmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\EcFBVOTZiaB?= MUTJcohq[mm2aX;uJI9nKF[HR1[tbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDJwN{Wg{txO M3\lXFIyPDVyNE[z
HUVEC M1ezUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOxOkBp NX3IT4o4UW6qaXLpeIlwdiCxZjDiSmdHNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjC0MlA1KM7:TR?= NUjzOnQzOjF2NUC0OlM>
IM9 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDxOZQ{OTZiaB?= NVrEWlV7SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTW06KGOnbHzz MWqyNVQ2ODR4Mx?=
K562 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\kPVZxOTZiaB?= NVO5c|RXSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsdy=> Mn\kNlE1PTB2NkO=
MDA-MB-231 M3vFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17JdFE3KGh? MUHBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{ MVqyNVQ2ODR4Mx?=
H460 MVHDfZRwfG:6aXOgRZN{[Xl? MXK3NkBp MlPNTWM2OD1{Lkeg{txO NYLDWHQ3OjF4MkG4PFA>
SMMC7721 Mn3UR5l1d3SxeHnjJGF{e2G7 NUDiSVFtPzJiaB?= NGjwWIVKSzVyPU[uOFch|ryP NWKwPGF6OjF4MkG4PFA>
WI38 MkWxR5l1d3SxeHnjJGF{e2G7 M{nHPFczKGh? NEC1O5lKSzVyPUiuOVYh|ryP MWGyNVYzOTh6MB?=
HEK293 MlvOT4lv[XOnIFHzd4F6 Ml\rNVAxKG6P NEe0eoUyKGh? M17O[YRw\XNibn;0JIlvcGmkaYSgWmVITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25ib3[geJlzd3OrbnWgNVE4PSC{ZYPp[JVmKG:wIG\FS2ZTOiCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{ MXyyNVg5PTJ6Nx?=
HUVEC MkjlSpVv[3Srb36gRZN{[Xl? M2HpV|Eh|ryP MlG3NlQhcA>? MX7BcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBXTUeILXnu[JVk\WRiY3XscEBucWe{YYTpc44> NELKSVUzOTl4M{OwOS=>
HUVEC MmPXSpVv[3Srb36gRZN{[Xl? NHG5[5EyKM7:TR?= M{OwWlEhcA>? NVTsPW44UW6qaXLpeIlwdiCxZjDFVmsheGixc4Doc5J6dGG2aX;uJIF1KFSqckKwNk9VgXJ{MESgbY4hXkWJRj3zeIlufWyjdHXkJGhWXkWF M3XV[|IyQTZ|M{C1
HUVEC MXPGeY5kfGmxbjDBd5NigQ>? MoHQNUDPxE1? M4jKflEhcA>? MYHJcohq[mm2aX;uJI9nKGWQT2OgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmei1zMUeyJIlvKF[HR1[td5RqdXWuYYTl[EBJXV[HQx?= MUSyNVk3OzNyNR?=
HUVEC NUnuWo9TU2mwYYPlJGF{e2G7 NEH4XZcyKM7:TR?= M2D6PVEhcA>? MnrlTY5pcWKrdHnvckBw\iCYRVfGVlIheGixc4Doc5J6dGG2aX;uJIF1KHS7cj2xNVc2KGmwIG\FS2Yue3SrbYXsZZRm\CCKVW\FRy=> MVGyNVk3OzNyNR?=
HUVEC MojTSpVv[3Srb36gRZN{[Xl? NWTUfJlJOSEQvF2= MXixJIg> MX;kc4V{KG6xdDDpcohq[mm2IFHLWEBxcG:|cHjvdplt[XSrb36gZZQhW2W{LUS3N{BqdiCYRVfGMZN1cW23bHH0[YQhUFWYRVO= Mn;HNlE6PjN|MEW=
HL60 NYTxU20{S3m2b4TvfIlkKEG|c3H5 MXW1NEDPxE1? NGXXNZI1QCCq MmS0SG1UVw>? NVX0RYJwUUN3ME2xOU42KM7:TR?= M2rHPVIzODF7MUi4
K562 M4r6fmN6fG:2b4jpZ{BCe3OjeR?= M4f5[lUxKM7:TR?= MYK0PEBp M3PoZWROW09? MWjJR|UxRTJzLkmg{txO NXXKcm9VOjJyMUmxPFg>
PC3 MVPDfZRwfG:6aXOgRZN{[Xl? M3HvdlUxKM7:TR?= NHy3NIQ1QCCq NVK4ZY5RTE2VTx?= MlS3TWM2OD1{NT6xJO69VQ>? MmDrNlIxOTlzOEi=
SF-539 MX3LbY5ie2ViQYPzZZk> M3v0OlM{OyEQvF2= NWLCOJI{PjBibXnu Mlj2TY5pcWKrdHnvckBw\iCSRFfGVoJmfGFidInyc5NqdmVia3nuZZNmKGGldHn2bZR6KGmwIGDES2YuSkJvc4TpcZVt[XSnZDDoeY1idiCVRj21N|kh[2WubIOge4l1cCCLQ{WwJI9nKDF{LkKg{txO NVPEfZBJOjJ{MES3OFE>
HAEC NWm1bYw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr2U2xHOTByIN88US=> Mom4O|IhcA>? NVvYZodVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIRWVEKGOnbHzzJIV5eHKnc4PpcochXkWJRmKge4l1cCCLQ{WwJI9nKDBwMTFOwG0> MUWyNlQ1PDZ5OR?=
HT-29 NXnCdGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu1NVAxKM7:TR?= NYPaTHI3PzJiaB?= M1LsO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOg[ZhxemW|c3nu[{BXTUeIUjD3bZRpKEmFNUCgc4YhOC5|MzFOwG0> MmXjNlI1PDR4N{m=
MV4-11 MoH2R5l1d3SxeHnjJGF{e2G7 MVO3NkBp NXq3PFlXUUN3ME2wMlAxOyEQvF2= NFTDUIwzOjR3MkWxPC=>
HepG2 M1vnXWN6fG:2b4jpZ{BCe3OjeR?= M4SzVlQ5KGh? M{W4RWlEPTB;MUOuNlQh|ryP M1XPcFIzPDh|NkC4
PC9 M{nIW2N6fG:2b4jpZ{BCe3OjeR?= M1e5UlQ5KGh? NVjRZYNPUUN3ME2xNE46PyEQvF2= MYOyNlQ5OzZyOB?=
CAKI-1 NWr5PZNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe1NVAxKM7:TR?= MmrvOFghcA>? NGG2XVNFVVOR NGDMVWFIUTVyPUCuOlMh|ryP NVPROItWOjJ3NkC2Nlc>
EKVX NUT4V4NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TQblExOCEQvF2= NFjRVpo1QCCq NXLoUGJwTE2VTx?= M360UWdKPTB;Nz65JO69VQ>? MljlNlI2PjB4Mke=
MCF7 NHvYbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkewNVAxKM7:TR?= MVG0PEBp NWPPW2JITE2VTx?= NXqxbGhCT0l3MU2yJO69VQ>? MYKyNlU3ODZ{Nx?=
MDA-MB-435 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f4WlExOCEQvF2= Ml\OOFghcA>? M2Xw[GROW09? NY[xdI1RT0l3Mk2yJO69VQ>? MViyNlU3ODZ{Nx?=
OVCAR3 NH;BSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H6TlExOCEQvF2= M1PyZVQ5KGh? MV;EUXNQ Mn7sS2k2Oz1|LkKg{txO NUXtV2U6OjJ3NkC2Nlc>
SNB19 M335Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOxNFAh|ryP NEXtcGM1QCCq NXvnfFhITE2VTx?= M3jK[2dKPTR;MUCg{txO MVmyNlU3ODZ{Nx?=
SW620 NVW3XWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVexNFAh|ryP M2n3eVQ5KGh? MXHEUXNQ NHW3U3hIUTV3PUGuN{DPxE1? NGq5WmozOjV4ME[yOy=>
TK10 NHrtZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoraNVAxKM7:TR?= MmTnOFghcA>? M1jHRWROW09? NVTab|lpT0l3Nk22MlMh|ryP M1vyN|IzPTZyNkK3
UACC257 MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKxNFAh|ryP M{DMWFQ5KGh? NHjEXHFFVVOR MWrHTVU4RTRizszN MYiyNlU3ODZ{Nx?=
HAEC M37t[mN6fG:2b4jpZ{BCe3OjeR?= MlHtNVAxKM7:TR?= MoHvO|IhcA>? M2TTZ2ROW09? MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBXTUeIUjDlfJBz\XO|aX7nJGhCTUNid3n0bEBKSzVyIH;mJFAvOSEQvF2= M{XmRVI{OTNzNUSx
HT-29 MXzDfZRwfG:6aXOgRZN{[Xl? NVnJRYFHOTByIN88US=> M3HyW|czKGh? MU\EUXNQ MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBXTUeIUjDlfJBz\XO|aX7nJIh2dWGwIFjUMVI6KGOnbHzzJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>? MVuyN|E{OTV2MR?=
HCT116 NXHYNph1TnWwY4Tpc44hSXO|YYm= MmjaNlQhcA>? MX;EUXNQ MYjBcpRqdWmpcnH0c5J6KGGldHn2bZR6KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2WubDDtbYdz[XSrb36= NX3jdZROOjNzNUOyNFA>
HUVEC NIe0R|RHfW6ldHnvckBCe3OjeR?= NITFSFgzKM7:TR?= NWTpS5hoOThiaB?= NGrMfIdFVVOR NGDHb4RCdnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQ4OgeY5l\XJiaInwc5hq[yClb37kbZRqd25iYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dXLlJIZwem2jdHnvci=> MlSxNlMyPTN{MEC=
ACHN NX3oe2c6S3m2b4TvfIlkKEG|c3H5 M1vzPFYh\A>? M2fvXWlEPTB;Mj61JO69VQ>? MXKyN|M3ODFyNB?=
A498 NInvcFBEgXSxdH;4bYMhSXO|YYm= MUexNFAh|ryP NEX3e4s4OiCq MUnEUXNQ Mo\TTWM2OD12LkOg{txO MlW4NlM1QDl4Mk[=
HUVEC NIXRZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLTRoxXOyEQvF2= NWHJbZVFOjRiaB?= MmjNSG1UVw>? MoGzRY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgeJVj\SCob4LtZZRqd25id3n0bEBGSzVyIH;mJFAvPjR3IN88US=> MoC2NlM2QDN7MUG=
HUVEC Mni0T4lv[XOnIFHzd4F6 M3T4TlIxOCEQvF2= MmPKSG1UVw>? NU\rVlhxUW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKGmwIHfyc5d1cCCoYXP0c5Iue3SrbYXsZZRm\CCKVW\FRy=> M2raU|I{PTh|OUGx
HUVEC M{TQU2tqdmG|ZTDBd5NigQ>? M3HuSlIxOCEQvF2= NH3lOpZFVVOR NEW4PYtKdmirYnn0bY9vKG:oIG\FS2ZTOSCyaH;zdIhwenmuYYTpc44hcW5iZ4Lve5RpKG[jY4Tvdk1{fGmvdXzheIVlKEiXVlXD NVjkU3dsOjN3OEO5NVE>
A549 NYruXlVDS3m2b4TvfIlkKEG|c3H5 NX\YXVl3PzJiaB?= NFz6d|lFVVOR NEK4cZRKSzVyPUKuOFQh|ryP MlLRNlM3ODJ2NEG=
HCT116 NWfZNGN6S3m2b4TvfIlkKEG|c3H5 MXS3NkBp MYTEUXNQ NWHvVlk5UUN3ME20MlcyKM7:TR?= MYWyN|YxOjR2MR?=
MCF7 MXzDfZRwfG:6aXOgRZN{[Xl? MUW3NkBp NVLqbm5bTE2VTx?= NYjDcFVUUUN3ME22MlI6KM7:TR?= MX6yN|YxOjR2MR?=
BGC NF\4R2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Wx[VczKGh? MVXEUXNQ NGnCXppKSzVyPUSuO|gh|ryP NF;QW|gzOzl7OUC0NC=>
BxPC3 NVzkbXEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHYO|IhcA>? NXPKNoFETE2VTx?= M{f3XGlEPTB;Mz62N{DPxE1? MofGNlM6QTlyNEC=
HT-29 NE\pbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXKO|IhcA>? NHXsfZJFVVOR M4izdWlEPTB;MT60O{DPxE1? M{LYR|I{QTl7MESw
T24 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIryU3I4OiCq MmfiSG1UVw>? MnfDTWM2OD1{LkS0JO69VQ>? NFnuNG8zOzl7OUC0NC=>
4T1 NHHtVWxEgXSxdH;4bYMhSXO|YYm= MkTYO|IhcA>? M3O1[GROW09? M3\jN2lEPTB;MD6wNVYh|ryP M{L5elI1QDlyNkWy
MCF7 M1Th[GN6fG:2b4jpZ{BCe3OjeR?= MoHwO|IhcA>? NILjemZFVVOR M3uzOWlEPTB;MD6wNlcyKM7:TR?= NVPsXW43OjR6OUC2OVI>
MCF7 NFPKUYREgXSxdH;4bYMhSXO|YYm= NIXiUoY4OiCq NGizemlFVVOR NYjqTGdqUUN3ME2wMlAzQTNizszN MVWyOFg6ODZ3Mh?=
MDA-MB-231 NX:4dHhrS3m2b4TvfIlkKEG|c3H5 M3K2XFczKGh? MVHEUXNQ MXvJR|UxRTBwMEKyN{DPxE1? NGTlO2UzPDh7ME[1Ni=>
MDA-MB-435 MYnDfZRwfG:6aXOgRZN{[Xl? MYm3NkBp Ml;BSG1UVw>? NIDjVVhKSzVyPUCuNFA6PyEQvF2= MlfzNlQ5QTB4NUK=
MDA-MB-468 NUew[WU6S3m2b4TvfIlkKEG|c3H5 MYe3NkBp MmO1SG1UVw>? NIHlTVdKSzVyPUCuNFA3OSEQvF2= MWqyOFg6ODZ3Mh?=
A431 MXLLbY5ie2ViQYPzZZk> MVOxNEDPxE1? MnTMNUBp M1m4TGROW09? M3rqTWlvcGmkaYTpc44hd2ZiRVfGVkB4cXSqIFnDOVAhd2ZiMD6xO|IyKM7:TR?= NYrmWYhFOjR6OUC2OVI>
SH-SY5Y NWXoV|BXU2mwYYPlJGF{e2G7 MWGxNEDPxE1? MkDTNUBp NInXe3BFVVOR NGXqWXVKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTD3bZRpKEmFNUCgc4YhOC5yOEOxJO69VQ>? M4jmbFI1QDlyNkWy
U251 NEC0fYVMcW6jc3WgRZN{[Xl? M1LF[|ExKM7:TR?= NYe3OVI6OSCq M1vBcGROW09? MVzJcohq[mm2aX;uJI9nKF[HR1\SNkB4cXSqIFnDOVAhd2ZiMD6wNVg6KM7:TR?= MkXPNlQ5QTB4NUK=
Bel7402 Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T0O|czKGh? MoT2SG1UVw>? MnHITWM2OD1{Lk[3JO69VQ>? MVyyOFkxPDl4MR?=
HK2 NGrSOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rRflczKGh? MlzHSG1UVw>? NH61VlRKSzVyPUWuPFUh|ryP MlPsNlQ6ODR7NkG=
LO2 NUfCNFFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG3NkBp MYrEUXNQ NEHENmtKSzVyPUG5Mlk{KM7:TR?= NWTYWVBKOjR7MES5OlE>
MV4-11 MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LCSFQ5KGh? MlzLSG1UVw>? MkO4TWM2OD1yLkCwN{DPxE1? MUeyOFkxPDl4MR?=
NCI-H3122 NGThdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXlO|IhcA>? M{XIW2ROW09? MnLETWM2OD1yLkizJO69VQ>? NGPiVo0zPDlyNEm2NS=>
NCI-H460 MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[3NkBp NGTrUGlFVVOR M3S4TGlEPTB;ND6zNUDPxE1? NHvJTWYzPDlyNEm2NS=>
NCI-H526 NVqwU4x2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVO3NkBp MX\EUXNQ NXjYd2ZrUUN3ME2xMlAyKM7:TR?= NVrQPY1QOjR7MES5OlE>
TT NIT2cWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXWO|IhcA>? MXrEUXNQ MWPJR|UxRTBwMESg{txO M1zoe|I1QTB2OU[x
EoL-1-cell NWrTcmwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwNkSgdG0> MnrZV2FPT0WU
MV-4-11 NI\QcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULV[|Q{UUN3ME2yO|IheE1? NIfzfZFUSU6JRWK=
NOS-1 NEDnWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\EOGFKSzVyPUG1MlMhdk1? M1jMXXNCVkeHUh?=
CGTH-W-1 MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjnTWM2OD1|MD65OEBvVQ>? MXTTRW5ITVJ?
MONO-MAC-6 NHnVO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTN|Lkigcm0> MknSV2FPT0WU
ALL-PO M2jlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnPZ3dyUUN3ME23PU45QSCwTR?= M{KxZnNCVkeHUh?=
NKM-1 MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTl6LkWyJI5O NVX0d3ZkW0GQR1XS
KM12 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILYVo5KSzVyPUO1NE4yPCCwTR?= NIXUeVRUSU6JRWK=
TE-15 M4\MSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D3V2lEPTB;NUC3MlYyKG6P MkjoV2FPT0WU
697 NEj6[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTZzND6yOUBvVQ>? MYTTRW5ITVJ?
MOLT-16 NXXONHRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXJTWM2OD14M{GuN|Ihdk1? M{niS3NCVkeHUh?=
GB-1 NV\xV3VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfYTWM2OD15MUCuNlMhdk1? MkDPV2FPT0WU
TE-12 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL1TWM2OD16MESuOVUhdk1? NX2zVlliW0GQR1XS
ES6 M2XQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m0NWlEPTB;OUixMlA3KG6P Ml62V2FPT0WU
LC-2-ad NGGxNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjBWI9DUUN3ME2xMlEyPDB5IN88US=> NXfvN5lZW0GQR1XS
BL-70 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjBVmNKSzVyPUGuNVE5PDZizszN NHG0fG9USU6JRWK=
ETK-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HIWWlEPTB;MT6yPFU5KM7:TR?= MWjTRW5ITVJ?
A4-Fuk NH2wZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDOTWM2OD1zLkO0NVQyKM7:TR?= M331OnNCVkeHUh?=
OCI-AML2 MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnGO|JKSzVyPUGuN|Y5PTFizszN NG\sTmpUSU6JRWK=
SIG-M5 M1jvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7rR4ZkUUN3ME2xMlM4ODB7IN88US=> M2PHTHNCVkeHUh?=
NCI-SNU-16 NIDhRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPLTWM2OD1zLkS2OFg3KM7:TR?= NEPZOHhUSU6JRWK=
PSN1 NYTiZpBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPlTWM2OD1zLkWwOlc3KM7:TR?= NFTwUItUSU6JRWK=
SR NYjYdFhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX73ZoVNUUN3ME2xMlU1PTd{IN88US=> MWnTRW5ITVJ?
A3-KAW NVLZVnRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwNkK1OFYh|ryP MYXTRW5ITVJ?
KS-1 NUHOe5R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFwNkmyOFch|ryP NILWS3RUSU6JRWK=
CTV-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDQc3JCUUN3ME2xMlczPzVzIN88US=> NGD4bGVUSU6JRWK=
LB1047-RCC NIq4PHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LId2lEPTB;MT64NVYzPCEQvF2= M{jKOXNCVkeHUh?=
EMG-01 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwOEO1OlMh|ryP NHrLTYtUSU6JRWK=
TE-11 NYOyXFZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vnVGlEPTB;MT64N|k5PSEQvF2= M4[yWHNCVkeHUh?=
CMK NGX4blZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2npNmlEPTB;MT65OVUyPyEQvF2= NYrVS|g5W0GQR1XS
NB1 M4HEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\GRWlEPTB;MT65OlEyPyEQvF2= M4K5UHNCVkeHUh?=
HAL-01 MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorBTWM2OD1{LkC1PVQ3KM7:TR?= NG\YeVdUSU6JRWK=
DEL NUXlPYh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwMEi0PFIh|ryP NGOzc2lUSU6JRWK=
RL95-2 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULwSIs{UUN3ME2yMlEyOTN5IN88US=> NXmzfGw1W0GQR1XS
KARPAS-299 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnrTWM2OD1{LkGxN|E{KM7:TR?= MW\TRW5ITVJ?
EW-16 M1vGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJwMUO1NFgh|ryP M2mxW3NCVkeHUh?=
RS4-11 NGrMNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIWyNlNKSzVyPUKuNVc6OjRizszN NFL6ZolUSU6JRWK=
BB30-HNC NFnIRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj0WpRKSzVyPUKuNlI{PzVizszN MYLTRW5ITVJ?
DOHH-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJwM{O0N|Eh|ryP MkG0V2FPT0WU
RPMI-8402 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDnPYVKSzVyPUKuN|M3OThizszN Mk\iV2FPT0WU
BV-173 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJwM{O2OkDPxE1? NIPjWnFUSU6JRWK=
TE-10 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnmVXdKSzVyPUKuN|Q{QDRizszN Mlv3V2FPT0WU
TE-8 M2jhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJwM{ewN|gh|ryP M{fmdXNCVkeHUh?=
K052 NGPTdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJwNECyNFIh|ryP NFjndIVUSU6JRWK=
KARPAS-45 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrUcIhKSzVyPUKuOFk1PDZizszN NEPYTJFUSU6JRWK=
SK-NEP-1 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzBTWM2OD1{Lk[wNlM4KM7:TR?= MV;TRW5ITVJ?
KGN NYPnWYg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTNTWM2OD1{Lk[wN|M6KM7:TR?= M33kRnNCVkeHUh?=
ML-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjYSGtEUUN3ME2yMlY{PTF{IN88US=> NXT1[nU6W0GQR1XS
LAMA-84 NWX0V4RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TITWlEPTB;Mj62PVU1PSEQvF2= NX7KXI1rW0GQR1XS
LXF-289 M1m1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m2NWlEPTB;Mj63Nlk5QSEQvF2= Mnn2V2FPT0WU
A101D NIDQeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXab4pKSzVyPUKuO|g{ODRizszN NVu3boxYW0GQR1XS
KY821 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CyZWlEPTB;Mj63PVc2QCEQvF2= NXe1N2dkW0GQR1XS
ES4 NYW1V|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C3NmlEPTB;Mj64NFYzQCEQvF2= NX3GZWFQW0GQR1XS
SCC-3 NHPCdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf3TFJKSzVyPUKuPFI5QTFizszN MWjTRW5ITVJ?
NALM-6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqzTWM2OD1{LkmwOFc{KM7:TR?= M4fCb3NCVkeHUh?=
BL-41 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFruUWNKSzVyPUKuPVEzOjJizszN MUfTRW5ITVJ?
OPM-2 MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H4SGlEPTB;Mz6wOVk2PCEQvF2= MnvXV2FPT0WU
SF126 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDYVmlbUUN3ME2zMlA3OTl6IN88US=> M2SwSHNCVkeHUh?=
BE-13 M1PKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomxTWM2OD1|LkKzNVEyKM7:TR?= NYm5TWJkW0GQR1XS
SF268 NIHYTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fXcWlEPTB;Mz6zNlg3QSEQvF2= M1jjcHNCVkeHUh?=
MOLT-4 NI[4SlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi1TWM2OD1|LkO5PFM5KM7:TR?= MWXTRW5ITVJ?
PF-382 M1rlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILLNo9KSzVyPUOuOFQ2PyEQvF2= MnKzV2FPT0WU
HEL MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrWUHpKSzVyPUOuOFgxODVizszN MmfKV2FPT0WU
RPMI-6666 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXniR4dEUUN3ME2zMlU1OTdzIN88US=> MknzV2FPT0WU
QIMR-WIL M1LhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTNwNkOzPVEh|ryP M3PpWXNCVkeHUh?=
ATN-1 NEHJNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILmdWdKSzVyPUOuOlcyOTRizszN MlXnV2FPT0WU
BB49-HNC NYj3dolYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTETWM2OD1|LkewOVA5KM7:TR?= NEn2WndUSU6JRWK=
HCE-4 NGL1VIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnjNI5KSzVyPUOuO|g3PDJizszN MlzuV2FPT0WU
SK-LMS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTNwOEOzN|gh|ryP M4XXfnNCVkeHUh?=
MS-1 NWC4W3hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNwOEO3O|gh|ryP NWXZUYVvW0GQR1XS
JAR NGjOfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwOUi4N|Ih|ryP NFzFOlJUSU6JRWK=
KE-37 M3naZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTRwME[xOVgh|ryP MlzEV2FPT0WU
LB996-RCC NXv1O2FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HuNGlEPTB;ND6xNlE3QCEQvF2= MnHaV2FPT0WU
HH MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjiOZZKSzVyPUSuNlA6OTRizszN NIfPUY9USU6JRWK=
HL-60 NF31UIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S2NWlEPTB;ND6yNVA3PSEQvF2= M2jk[XNCVkeHUh?=
HOP-62 MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Tv[2lEPTB;ND6zN|UzKM7:TR?= NWDkeoRwW0GQR1XS
NOMO-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLEUY5FUUN3ME20MlM{Pjl7IN88US=> MWnTRW5ITVJ?
DU-4475 M1PkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTRwM{[3Nlkh|ryP NUHoZ2JZW0GQR1XS
LC4-1 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorPTWM2OD12LkO4NFch|ryP NVryVlBYW0GQR1XS
MC116 M4LjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG2dWViUUN3ME20MlQ{ODhzIN88US=> M{P6VHNCVkeHUh?=
SW982 M121ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn6W5lKSzVyPUSuOVU{ODdizszN M2Loc3NCVkeHUh?=
SK-N-DZ NHjWRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPsUZBKSzVyPUSuOlcxQTlizszN MUDTRW5ITVJ?
EW-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTRwNke5NVEh|ryP M1joRnNCVkeHUh?=
SU-DHL-1 MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P2S2lEPTB;ND64NFE4PCEQvF2= MljZV2FPT0WU
L-363 NHvIVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDXcplKSzVyPUSuPFA3OjFizszN Ml[4V2FPT0WU
OS-RC-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUCwOIFJUUN3ME20Mlg4OzFizszN NHf2UIFUSU6JRWK=
HD-MY-Z NWW4cpM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;DfYJKSzVyPUWuNVc{ODFizszN MmP6V2FPT0WU
MHH-PREB-1 M13B[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i2fGlEPTB;NT6zNlMyOiEQvF2= MXPTRW5ITVJ?
HC-1 M4WyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTVwNEOyPVEh|ryP MmHIV2FPT0WU
SK-MM-2 NXi3XlN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy5dFljUUN3ME21MlQ4QDJizszN MWHTRW5ITVJ?
SH-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnQRpVXUUN3ME21MlQ5OzdizszN NEPrfG1USU6JRWK=
MHH-CALL-2 M1\jNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe2TWM2OD13Lke2O|E6KM7:TR?= NGPkeI5USU6JRWK=
KG-1 Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrsXVZnUUN3ME22MlAzQDd6IN88US=> M4O3[3NCVkeHUh?=
J-RT3-T3-5 NES1WFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHSbIxKSzVyPU[uNFc6ODlizszN MlzPV2FPT0WU
MMAC-SF Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTZwMUC5OFkh|ryP NXzYZYJ3W0GQR1XS
IST-SL2 M36xO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTZwMUK1NVkh|ryP Mm\3V2FPT0WU
SW954 NF[xfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jod2lEPTB;Nj6yO|UyPyEQvF2= NXm4UIt5W0GQR1XS
HDLM-2 NUXBeWN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTuW41MUUN3ME22MlMzOTB7IN88US=> NUS4S|Y1W0GQR1XS
ST486 M{DwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4eybmlEPTB;Nj6zOFcyKM7:TR?= NGrLWVRUSU6JRWK=
DG-75 M2XEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7EV5dJUUN3ME22MlQ{ODZ7IN88US=> NX3tRm9rW0GQR1XS
EW-3 NHXkdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7VTWM2OD14LkSzNlA4KM7:TR?= M1XKOHNCVkeHUh?=
8-MG-BA M4TFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTZwNUG1NFch|ryP MmjzV2FPT0WU
GT3TKB MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTZwNkC3OlMh|ryP NGjTWI9USU6JRWK=
KU812 NX75WIlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv5OGgxUUN3ME22MlY6PDJizszN M{nkSnNCVkeHUh?=
CESS MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPlTWM2OD15LkGwOFM5KM7:TR?= MmrjV2FPT0WU
BC-1 NY[4RotGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv2TWM2OD15LkK0PFEzKM7:TR?= M2DNOHNCVkeHUh?=
MZ1-PC Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLYTWM2OD15LkOwN|g6KM7:TR?= MUnTRW5ITVJ?
NCI-H82 MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7HRpdpUUN3ME23MlM4QDVizszN M1fRZnNCVkeHUh?=
NCI-H1355 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX25eIRJUUN3ME23MlQ2QDB2IN88US=> NYDvVoFsW0GQR1XS
RPMI-8226 NFLodHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPOTWM2OD15LkWwO|M6KM7:TR?= MUPTRW5ITVJ?
ARH-77 NUXiN3IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr4V3lDUUN3ME23MlU{PTl5IN88US=> MVPTRW5ITVJ?
MN-60 NXr2UW5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DEOmlEPTB;Nz61OFA5QCEQvF2= M{TnNHNCVkeHUh?=
IMR-5 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf0UIxKSzVyPUewOVQ5PzZizszN M3zCeHNCVkeHUh?=
KARPAS-422 NGi3UIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\Bd4xUUUN3ME23MlU4OjB4IN88US=> M4HoNnNCVkeHUh?=
CA46 NVW5Z2ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDwfItKUUN3ME23MlU5ODF{IN88US=> NIe3SotUSU6JRWK=
SJSA-1 NVnjc2JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HsTWlEPTB;Nz62OlA3OSEQvF2= NWLzOGR3W0GQR1XS
no-11 NVHUVpJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLFTWM2OD15Lke3OVU4KM7:TR?= MXXTRW5ITVJ?
IST-SL1 MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G1b2lEPTB;OD6wNlQyPyEQvF2= NWDs[YU1W0GQR1XS
NCI-H209 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUKxeI5bUUN3ME24MlEyPjV{IN88US=> M2P1OnNCVkeHUh?=
TALL-1 M2njZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rVSWlEPTB;OD6xPFM5PCEQvF2= MYnTRW5ITVJ?
KMOE-2 MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{mycmlEPTB;OD6xPVQzKM7:TR?= NEDaVYJUSU6JRWK=
HCC1599 NWnIPJAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIflTHRKSzVyPUiuNVk6QDdizszN NYrpbppDW0GQR1XS
CI-1 NUPNOIpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLNZok{UUN3ME24MlIxPDFzIN88US=> NIj0cmxUSU6JRWK=
NCI-H1304 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSwO41PUUN3ME24MlIxPjZzIN88US=> Mn\4V2FPT0WU
Daudi M161e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rYc2lEPTB;OD6yN|U1PiEQvF2= NYnQbnBuW0GQR1XS
CPC-N MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRThwMkmxPVkh|ryP NXLy[Gg1W0GQR1XS
MC-CAR NI\MSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrU[XlGUUN3ME24MlM{PThizszN NXLKcItzW0GQR1XS
SW872 MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfPTWM2OD16LkO0O|U5KM7:TR?= NGLYXm5USU6JRWK=
OVCAR-4 M{f6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq5NlJKSzVyPUiuOVA{PTFizszN MoDvV2FPT0WU
OCUB-M M1nHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXKTWM2OD16LkW2OVA5KM7:TR?= MWfTRW5ITVJ?
SK-PN-DW MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfyVpg6UUN3ME24MlYxQTh3IN88US=> MYfTRW5ITVJ?
NCCIT MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\h[WlEPTB;OD63NVc1PSEQvF2= MYfTRW5ITVJ?
NCI-H1648 M1LQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTlwMUO4N|Qh|ryP MoP3V2FPT0WU
COR-L279 NXXSc4c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PjXGlEPTB;OT6zPVA6KM7:TR?= NGm1RoFUSU6JRWK=
LS-123 M{S2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTsdYFNUUN3ME25MlY5OTZzIN88US=> NWDYWlI{W0GQR1XS
LP-1 NFOyUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLZTWM2OD17Lke4NFg{KM7:TR?= M13INHNCVkeHUh?=
NB13 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\NWGlEPTB;OT63PVk6PCEQvF2= NHT5XpZUSU6JRWK=
ONS-76 NVftbZpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTlwOEGwNVYh|ryP MmfsV2FPT0WU
VA-ES-BJ NFflOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\yTWM2OD17Lkm5PVM{KM7:TR?= MnnWV2FPT0WU
GR-ST MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK4dlhKSzVyPUGwMlIzODdizszN MYrTRW5ITVJ?
ES1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfjfG9KSzVyPUGwMlI6QDRizszN M{TFXnNCVkeHUh?=
NB14 NX7tRmpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULQSm9CUUN3ME2xNE46Ojd5IN88US=> MkL1V2FPT0WU
Ramos-2G6-4C10 M1XhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPNVm1KSzVyPUGxMlI3PSEQvF2= M{frWXNCVkeHUh?=
RXF393 NELYU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO2TWM2OD1zMT60PFM1KM7:TR?= NXO0WG9nW0GQR1XS
NCI-H2107 NIL3OVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFzLkW5PFQh|ryP NYezXJNKW0GQR1XS
K562 NYfwU3ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf3TWM2OD1zMT64O|AzKM7:TR?= MYLTRW5ITVJ?
LOUCY MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXwTWM2OD1zMT65PFc2KM7:TR?= Mm\MV2FPT0WU
TGBC1TKB NUXoWnR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD3e2RRUUN3ME2xNk4xODJizszN NYPrZpk4W0GQR1XS
COLO-320-HSR NG\lWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjjfGlKSzVyPUGyMlE2PjVizszN NVHqRYNuW0GQR1XS
K5 Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnR[5pOUUN3ME2xNk4zQTh3IN88US=> MoTIV2FPT0WU
BC-3 NVqxbIlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnhTWM2OD1zMj60OlUyKM7:TR?= MXnTRW5ITVJ?
REH M17S[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF{Lk[0PVgh|ryP M{TYeXNCVkeHUh?=
NEC8 M2izT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjnZWptUUN3ME2xNk43QDh5IN88US=> MVjTRW5ITVJ?
IST-MEL1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjlRpZKSzVyPUGyMlg3QTRizszN Mly4V2FPT0WU
NCI-H128 NXG4eXJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fzUGlEPTB;MUOuNFczOyEQvF2= M1;y[nNCVkeHUh?=
NCI-H1694 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zS[GlEPTB;MUOuNVE1PCEQvF2= NYPYWWFNW0GQR1XS
TGW MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF|LkOyO|Yh|ryP MlHJV2FPT0WU
NCI-SNU-1 M3XWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPRTWM2OD1zMz6zOFUh|ryP MWHTRW5ITVJ?
IST-MES1 M4XKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HwSGlEPTB;MUOuOlczQSEQvF2= NF7I[ZRUSU6JRWK=
CTB-1 NWPOPJFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fhUGlEPTB;MUOuO|I6PCEQvF2= MVzTRW5ITVJ?
HUTU-80 MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLBTWM2OD1zMz63OVc{KM7:TR?= MV\TRW5ITVJ?
LAN-6 NHviTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLzXGpKSzVyPUG0MlI1PTdizszN NFXUfmJUSU6JRWK=
KP-N-YS NWLnWJU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnybGJKSzVyPUG0MlI5QTRizszN NIrWUHJUSU6JRWK=
CCRF-CEM NIf1R3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXpTWM2OD1zND60NVY6KM7:TR?= NG\IZ45USU6JRWK=
NCI-H1770 NFvucFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HJRWlEPTB;MUSuOVM3QSEQvF2= MnHoV2FPT0WU
MZ2-MEL NVraWGFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TSemlEPTB;MUWuNlI2OSEQvF2= Mn;4V2FPT0WU
COR-L88 NHzUdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2WxOWlEPTB;MU[uNFAyOiEQvF2= MXXTRW5ITVJ?
LOXIMVI NXO3PXk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF4LkK1OkDPxE1? MX;TRW5ITVJ?
KALS-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:xTWM2OD1zNj61PVMyKM7:TR?= M3jxS3NCVkeHUh?=
D-283MED MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme5TWM2OD1zNj64OFg6KM7:TR?= NXrzRXJTW0GQR1XS
NCI-H719 MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF4LkmxOlEh|ryP NV7OfFNMW0GQR1XS
MLMA Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TEW2lEPTB;MU[uPVkxPyEQvF2= MoPFV2FPT0WU
EVSA-T M2jxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF5LkC0PFUh|ryP M2fWNnNCVkeHUh?=
SK-N-FI MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF5Lk[5NVMh|ryP MXvTRW5ITVJ?
NTERA-S-cl-D1 M2jBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELvUHVKSzVyPUG3Mlg2PzJizszN Moi4V2FPT0WU
NCI-H1882 M1noSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXwTWM2OD1zNz65PFM1KM7:TR?= M2fLdHNCVkeHUh?=
A704 M4HhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[yOnFbUUN3ME2xO{46QTB2IN88US=> MmTxV2FPT0WU
L-428 NEjLNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSzXo1vUUN3ME2xPE4xOTVzIN88US=> NXn5No56W0GQR1XS
HCC1187 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv5U|dKSzVyPUG4MlAyQDdizszN NHPUdlhUSU6JRWK=
NCI-H1581 M1Tze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGwTWM2OD1zOD6wPFY3KM7:TR?= NHfuTHhUSU6JRWK=
BB65-RCC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrV[VNKSzVyPUG4MlQyPjJizszN M4WyW3NCVkeHUh?=
EM-2 NXr2d2RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyzTWM2OD1zOD61OlczKM7:TR?= MlTZV2FPT0WU
Raji M4rIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnFOY1KSzVyPUG5Mlk2PjVizszN MkK2V2FPT0WU
TE-1 NEm4cppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS4TWM2OD1{MD60NVA1KM7:TR?= M3:5NXNCVkeHUh?=
SW962 MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVmwUY9ZUUN3ME2yNE41Ojl|IN88US=> MlnnV2FPT0WU
MHH-NB-11 NGTXe2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\wWYRzUUN3ME2yNE42PTJzIN88US=> MXnTRW5ITVJ?
no-10 NY\UOG5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJzLkCyOlQh|ryP NIXZWnhUSU6JRWK=
GDM-1 NWTtS3RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjLNlB2UUN3ME2yNU46PDF2IN88US=> NEHqdIJUSU6JRWK=
KMS-12-PE NHnIO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq1TWM2OD1{Mj6yO|Qh|ryP M3npR3NCVkeHUh?=
NCI-H510A MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfPTWM2OD1{ND6xNlc5KM7:TR?= NYq3UJQ{W0GQR1XS
ES5 NGjMUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ2LkezOFkh|ryP NXHPbno2W0GQR1XS
JiyoyeP-2003 M3i4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L2fGlEPTB;Mk[uNlc1OiEQvF2= NH:zeHZUSU6JRWK=
NMC-G1 M2rIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX2epdXUUN3ME2yO{4yQDJ{IN88US=> NXn6fI1kW0GQR1XS
NCI-H446 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJ5LkS5OFYh|ryP NHvMbXFUSU6JRWK=
NB7 Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK0fIJKSzVyPUK3MlkzOjlizszN M4rVbnNCVkeHUh?=
A388 MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\F[mlEPTB;MkiuNFA4PCEQvF2= MVHTRW5ITVJ?
JVM-2 M2\VNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm5T3dKSzVyPUK4MlI5QThizszN MljaV2FPT0WU
HT-144 NGX6XXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDlTWM2OD1{OD62PUDPxE1? M1zp[XNCVkeHUh?=
NCI-H747 M3e5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPvSXZKSzVyPUK4MlkyQTVizszN NUfFVmZUW0GQR1XS
NCI-H1650 M4DafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\DR2lEPTB;MkmuNFE4PiEQvF2= MUnTRW5ITVJ?
EB-3 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDDTWM2OD1{OT61N|A6KM7:TR?= NEfVeWtUSU6JRWK=
KLE M2XhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTFTWM2OD1{OT62NVkh|ryP MnHnV2FPT0WU
TK10 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNyLkGyOkDPxE1? NHj4[ZdUSU6JRWK=
COLO-668 M2T2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSxTGhJUUN3ME2zNE44QTJizszN MUnTRW5ITVJ?
NCI-H23 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHLOlh6UUN3ME2zNU4yODZ|IN88US=> NE\IbZFUSU6JRWK=
GOTO MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\6V3hKSzVyPUOxMlYxQDVizszN Mn\sV2FPT0WU
MSTO-211H NHTGSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojvTWM2OD1|MT64Olc5KM7:TR?= MXHTRW5ITVJ?
LB831-BLC MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrCPI5KSzVyPUOyMlM5PDNizszN NHHYR|BUSU6JRWK=
SCH MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLDNFlJUUN3ME2zNk45PDh3IN88US=> M{H6V3NCVkeHUh?=
EHEB NYTCcmRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTN2LkGxPVMh|ryP MV3TRW5ITVJ?
U-266 Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXGTWM2OD1|ND6yO|gyKM7:TR?= NXHM[2xGW0GQR1XS
EW-11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;1[WlEPTB;M{SuOFczPSEQvF2= NFftOmpUSU6JRWK=
TE-9 NFrFd2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX6TWM2OD1|Nz6wOFAyKM7:TR?= MlfkV2FPT0WU
ES3 NVXibZJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnQcoxTUUN3ME2zO{42ODB2IN88US=> M3:1WnNCVkeHUh?=
NCI-H2141 NEHqPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHy[ldKSzVyPUO4MlA5PDNizszN NY\Fb3UzW0GQR1XS
MPP-89 Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\iUmlEPTB;NEKuNFU5PiEQvF2= NVGyOoZ{W0GQR1XS
SK-MEL-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFGzO5RKSzVyPUSyMlY1ODVizszN MVPTRW5ITVJ?
LC-1F MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H1NWlEPTB;NEOuN|Y5OiEQvF2= MWrTRW5ITVJ?
NH-12 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjaSGpMUUN3ME20N{46OzV7IN88US=> MoLXV2FPT0WU
RKO NWm2WVRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLjN|dMUUN3ME20OE4yOjV{IN88US=> MnXqV2FPT0WU
KM-H2 NXfEWmt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;LUVFNUUN3ME20OE46PTd5IN88US=> MVHTRW5ITVJ?
SK-UT-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmOyTWM2OD12OT64PFI2KM7:TR?= NEm1R5pUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-ERK / ERK; 

PubMed: 24759734     


Effect of 72 h treatment with sunitinib on SH-SY5Y, SK N BE(2), SK-N-AS and IMR-32 NB cell lines analyzed by Western blot with pSer473Akt, Akt, pThr202/Thr204 Erk1/2 and Erk1/2 antibodies. β-actin was used as a loading control.

p-GSK3β / GSK3β / MYCN ; 

PubMed: 24759734     


Effect of sunitinib on GSK3β phosphorylation and on MYCN total protein in MYCN amplified NB cell lines.

p-STAT3 / STAT3 / p-Src / Src / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 19244102     


Sunitinib reduced Stat3 and Src activity, with no dramatic reduction of AKT, MAPK and JAK signaling in 786-O cells. Tumor cells were treated with sunitinib at indicated concentrations for 2 h (left panels) or 24 h (right panels). Total cell lysates were prepared and western blots were performed using relevant antibodies to detect total protein levels, with β-actin used as the loading control.

24759734 19244102
Growth inhibition assay
Cell viability; 

PubMed: 24369536     


Isolated effects of sunitinib malate on urinary bladder-cancer cell lines viability, assessed by using the MTT assay. The data shown and bars represent the mean values ± SD (SD: standard deviation). *P < 0.05 versus untreated cells.

24369536
In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
- Collapse

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
- Collapse
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A
Smiles CCN(CC)CCNC(=O)C1=C(C)[NH]C(=C1C)/C=C/2C(=O)NC3=CC=C(F)C=C23.OC(CC(O)=O)C(O)=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01391962 Recruiting Drug: Cediranib|Drug: Sunitinib Sarcoma Alveolar Soft Part National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 19 2011 Phase 2
NCT01073644 Terminated Drug: Sunitinib malate Metastatic Renal Cell Carcinoma Pfizer February 2010 --
NCT00912912 Terminated Drug: Sunitinib Malate Genitourinary Disease M.D. Anderson Cancer Center|Pfizer May 2009 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID